MEDIPOST enters into new business and accelerates its clinical trials in the U.S. through third-party allotment financing2022/03/17MEDIPOST
MEDIPOST starts cord blood-derived immune cell therapy development with the establishment of its subsidiary “IMMUNIQUE”2021/04/02MEDIPOST
MEDIPOST enters an agreement with LG Chem to transfer its MLSC technology, a next-generation cell culture platform technology, to develop gene and cell therapy products2020/12/23MEDIPOST
MEDIPOST’s CEO Dr Yang Yoonsun Named on the Forbes 2020 List of Asia’s Power Businesswomen2020/09/16MEDIPOST
MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.2022/12/01
Medipost to launch a CDMO business for cell and gene therapy products in Korea based on 20 years of research and production knowledge2022/10/17
Medipost enters North American market by acquiring OmniaBio, a CDMO company with cell and gene therapy products2022/05/31
